OQROGet OQRO Pro
Insider trade

Biocardia (BCDA)Director bought ~$150K

Andrew Scott Blank, Director at Biocardia, bought ~$150K of Biocardia shares.

~$150K
Approx. value · 72K sh @ $2.08
346K
Holds after · shares reported
Traded
Jun 30, 2025
Filed
Jul 3, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. May 14, 2025InsiderCEO purchased ~$299 of BCDA shares in the open market
  2. May 16, 2025InsiderCEO purchased ~$730 of BCDA shares in the open market
  3. May 20, 2025InsiderCEO purchased ~$3.3K of BCDA shares in the open market
  4. May 22, 2025InsiderCEO purchased ~$1.3K of BCDA shares in the open market
  5. May 30, 2025InsiderCEO purchased ~$221 of BCDA shares in the open market
  6. Jun 30, 2025 · this disclosureInsiderDirector purchased ~$150K of BCDA shares in the open market

What came next

  1. Jun 30, 2025Insider · 3 peopleInsiders: 3 purchases (~$210K)
  2. Aug 11, 2025InsiderCEO purchased ~$3K of BCDA shares in the open market
  3. Aug 12, 2025InsiderCEO purchased ~$700 of BCDA shares in the open market
  4. Aug 13, 2025InsiderCEO purchased ~$183 of BCDA shares in the open market
  5. Aug 22, 2025InsiderCEO purchased ~$1.3K of BCDA shares in the open market
  6. Sep 19, 2025Insider · 3 peopleInsiders: 3 purchases (~$918K)
  7. Sep 24, 2025Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“As previously disclosed on that certain Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 4, 2025 (the “Original 8-K”), on April 1, 2025, BioCardia, Inc. (the “Company,” “we,” “us” and “our”) received a notification letter (the “Notice”) from the Nasdaq Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its…”
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Biocardia

For Biocardia, OQRO holds 9 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BCDA page.

Other recent filings by Andrew Scott Blank, Director

The full history of Andrew Scott Blank, Director is on the profile page.

How this filing works

Other disclosures at Biocardia

Everything OQRO holds on this company is on its BCDA page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data